Market Scope

Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis

Choose Your Experience

Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

9/27/2024
BreakingCataractSurgical
Zeiss Announces Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery
Zeiss Announces Broad US Rollout of Micor 700 for Phaco-less Cataract Surgery

Carl Zeiss Meditec reported Sept. 26 that it had begun broad US distribution of the Micor 700, the first hand-held device to extract a crystalline lens in cataract surgery without the need for ultr...

9/27/2024
BreakingEuropeGlaucomaPharmaRegulation
AbbVie Withdraws EU Marketing Application for Durysta
AbbVie Withdraws EU Marketing Application for Durysta

Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...

9/27/2024
BreakingDealsGlaucomaRetina
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate
Nicox, Glaukos Sign Research and Option Agreement for Glaucoma Candidate

France’s Nicox announced Sept. 23 that it had signed an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5...

9/27/2024
BreakingPharmaRegulation
Tepezza Receives Approval in Japan to Treat Active Thyroid Eye Disease
Tepezza Receives Approval in Japan to Treat Active Thyroid Eye Disease

Amgen reported Sept. 24 that Tepezza had gained approval in Japan for the treatment of active or high clinical activity score thyroid eye disease (TED). The Thousand Oaks, California, company said ...

9/27/2024
BiosimilarsBreakingPharmaRetina
Amgen’s Pavblu is Fifth Aflibercept Biosimilar to Gain US Approval in 2024
Amgen’s Pavblu is Fifth Aflibercept Biosimilar to Gain US Approval in 2024

The FDA has approved Amgen’s Pavblu (aflibercept-ayyh), making it the fifth Eylea biosimilar to reach the milestone in the US in 2024. FDA records show Pavblu was approved Aug. 23. Labeling shows i...

9/27/2024
BiosimilarsBreakingEuropeRetina
Europe’s CHMP Recommends Two Aflibercept Biosimilars for Approval
Europe’s CHMP Recommends Two Aflibercept Biosimilars for Approval

Europe’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on Sept. 19 for two new aflibercept (Eylea) biosimilars—Afqlir from Swiss drugmaker Sandoz and Opuviz, which ...

9/27/2024
BreakingDealsInstrumentsRetinaSurgical
Microsurgical Technology (MST) to Commercialize Vista Vitrectomy Products
Microsurgical Technology (MST) to Commercialize Vista Vitrectomy Products

Microsurgical Technology (MST) announced Sept. 17 that it had partnered with Vista Ophthalmics to commercialize Vista’s products—the Vista 1-Step vitrectomy probe and the Vista IS for maintaining t...

9/27/2024
BreakingGene TherapyIndustryRetina
AAVantgarde Bio Appoints Jayashree Sahni, MD, as Chief Medical Officer
AAVantgarde Bio Appoints Jayashree Sahni, MD, as Chief Medical Officer

Italy’s AAVantgarde Bio announced Sept. 9 that it had appointed Jayashree Sahni, MD, FRCOphth, EMBA, as chief medical officer. Sahni, a retina specialist, was senior global program clinical head at...

Provider Surveys & Interviews

Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Table of Innovation

Choose Your Own Adventure

Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.

Safe, Secure & On Any Device

We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.

Pre-Qualified Invitations

We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.

Better Data = Better Decisions

A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.

Market Scope+ App Screen

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Disease models
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Join Market Scope Today

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

Select your country...